Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pioglitazone and Carboplatin in Advanced Solid Tumors
NCT02133625Phase 1Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Aug 2011
- Primary completion
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of pioglitazone in solid tumor (2 arms), sponsored by Dana-Farber Cancer Institute. Primary endpoint: Maximum Tolerated Dose at 6 weeks. Started Aug 2011; status: completed.
02
Drugs
pioglitazone
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02133625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02133625.